Jounce Therapeutics, Inc. – NASDAQ:JNCE

Financial Health
0
1
2
3
4
5
6
7
8
9

Jounce Therapeutics stock price monthly change

+1.62%
month

Jounce Therapeutics stock price quarterly change

+55.37%
quarter

Jounce Therapeutics stock price yearly change

-63.21%
year

Jounce Therapeutics key metrics

Market Cap
98.95M
Enterprise value
N/A
P/E
-1.85
EV/Sales
-1.71
EV/EBITDA
2.88
Price/Sales
N/A
Price/Book
N/A
PEG ratio
-0.04
EPS
-0.98
Revenue
N/A
EBITDA
-50.15M
Income
-50.91M
Revenue Q/Q
315384515.38%
Revenue Y/Y
204.75%
Profit margin
-62.1%
Oper. margin
-63.71%
Gross margin
0%
EBIT margin
-63.71%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Jounce Therapeutics stock price history

Jounce Therapeutics stock forecast

Jounce Therapeutics financial statements

Jounce Therapeutics, Inc. (NASDAQ:JNCE): Profit margin
Mar 2022 0 -37.36M
Jun 2022 0 -33.51M
Sep 2022 0 -30.99M
Dec 2022 82M 50.95M 62.15%
Jounce Therapeutics, Inc. (NASDAQ:JNCE): Earnings per share (EPS)
2022-08-04 -0.68 -0.65
2022-11-10 -0.64 -0.6
Jounce Therapeutics, Inc. (NASDAQ:JNCE): Debt to assets
Mar 2022 214671000 25.70M 11.98%
Jun 2022 188901000 31.17M 16.5%
Sep 2022 158081000 28.72M 18.17%
Dec 2022 212550000 29.43M 13.85%
Jounce Therapeutics, Inc. (NASDAQ:JNCE): Cash Flow
Mar 2022 -33.16M -2.36M 409K
Jun 2022 -23.40M 40.70M 33K
Sep 2022 -31.54M 30.91M 0
Dec 2022 59.23M 14.22M 0

Jounce Therapeutics alternative data

Jounce Therapeutics, Inc. (NASDAQ:JNCE): Employee count
Aug 2023 141
Sep 2023 141
Oct 2023 141
Nov 2023 141
Dec 2023 141
Jan 2024 141
Feb 2024 141
Mar 2024 141
Apr 2024 141
May 2024 141
Jun 2024 141
Jul 2024 141

Jounce Therapeutics other data

83.17% +4.36%
of JNCE is owned by hedge funds
41.52M +1.14M
shares is hold by hedge funds

Jounce Therapeutics, Inc. (NASDAQ:JNCE): Insider trades (number of shares)
Period Buy Sel
Jan 2023 0 85085
Mar 2023 85987 0
Apr 2023 0 39228
Transaction Date Insider Security Shares Price per share Total value Source
Sale
MURRAY RICHARD /CA/ director Common Stock 39,228 $1.85 $72,572
Purchase
TANG KEVIN C 10 percent owner Common Stock 20,286 $1.02 $20,651
Purchase
TANG KEVIN C 10 percent owner Common Stock 65,701 $0.99 $65,307
Sale
COLE HUGH M officer: Chief Op.. Common Stock 9,182 $1.12 $10,284
Sale
DRAPKIN KIMBERLEE C officer: CFO and Treasurer
Common Stock 7,781 $1.12 $8,715
Sale
MURRAY RICHARD /CA/ director, officer.. Common Stock 24,879 $1.12 $27,864
Sale
TREHU ELIZABETH officer: Chief Medical Officer
Common Stock 5,126 $1.12 $5,741
Sale
COLE HUGH M officer: Chief Op.. Common Stock 7,452 $1.1 $8,197
Sale
DRAPKIN KIMBERLEE C officer: CFO and Treasurer
Common Stock 6,315 $1.1 $6,947
Sale
MURRAY RICHARD /CA/ director, officer.. Common Stock 20,191 $1.1 $22,210
Patent
Application
Filling date: 14 Dec 2021 Issue date: 8 Sep 2022
Grant
Filling date: 14 Jul 2020 Issue date: 14 Jun 2022
Application
Filling date: 10 Mar 2020 Issue date: 5 May 2022
Grant
Filling date: 14 May 2019 Issue date: 5 Apr 2022
Application
Filling date: 24 Oct 2019 Issue date: 9 Dec 2021
Application
Filling date: 25 Oct 2019 Issue date: 18 Nov 2021
Application
Filling date: 18 Oct 2019 Issue date: 18 Nov 2021
Application
Filling date: 5 Feb 2021 Issue date: 4 Nov 2021
Application
Filling date: 9 Feb 2021 Issue date: 9 Sep 2021
Application
Filling date: 16 Sep 2020 Issue date: 10 Jun 2021
Insider Compensation
Dr. Richard Murray (1959) Pres, Chief Executive Officer & Director $884,860
Mr. Hugh M. Cole (1965) Chief Bus. Officer & Head of Corporation Devel. $641,330
Ms. Kimberlee Cobleigh Drapkin CPA, CPA (1968) Chief Financial Officer & Treasurer
$582,390
Tuesday, 19 September 2023
businesswire.com
Tuesday, 28 March 2023
Zacks Investment Research
Friday, 17 March 2023
PennyStocks
Thursday, 16 March 2023
Zacks Investment Research
PennyStocks
PennyStocks
Wednesday, 15 March 2023
24/7 Wall Street
InvestorPlace
Friday, 24 February 2023
PennyStocks
Thursday, 23 February 2023
InvestorPlace
Thursday, 29 December 2022
Seeking Alpha
PennyStocks
Wednesday, 28 December 2022
InvestorPlace
Tuesday, 27 December 2022
Reuters
Market Watch
Thursday, 20 October 2022
GlobeNewsWire
Wednesday, 7 September 2022
GlobeNewsWire
Wednesday, 31 August 2022
Zacks Investment Research
Friday, 5 August 2022
Seeking Alpha
Tuesday, 17 May 2022
GlobeNewsWire
Saturday, 7 May 2022
Seeking Alpha
Thursday, 28 April 2022
GlobeNewsWire
Wednesday, 2 March 2022
Seeking Alpha
Zacks Investment Research
Wednesday, 23 February 2022
GlobeNewsWire
Thursday, 16 December 2021
Seeking Alpha
Tuesday, 9 November 2021
GlobeNewsWire
Thursday, 4 November 2021
Seeking Alpha
Thursday, 28 October 2021
GlobeNewsWire
Thursday, 7 October 2021
GlobeNewsWire
  • When is Jounce Therapeutics's next earnings date?

    Unfortunately, Jounce Therapeutics's (JNCE) next earnings date is currently unknown.

  • Does Jounce Therapeutics pay dividends?

    No, Jounce Therapeutics does not pay dividends.

  • How much money does Jounce Therapeutics make?

    Jounce Therapeutics has a market capitalization of 98.95M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 204.75% to 82M US dollars. Jounce Therapeutics made a loss 50.92M US dollars in net income (profit) last year or -$0.6 on an earnings per share basis.

  • What is Jounce Therapeutics's stock symbol?

    Jounce Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "JNCE".

  • What is Jounce Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Jounce Therapeutics?

    Shares of Jounce Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Jounce Therapeutics's key executives?

    Jounce Therapeutics's management team includes the following people:

    • Dr. Richard Murray Pres, Chief Executive Officer & Director(age: 66, pay: $884,860)
    • Mr. Hugh M. Cole Chief Bus. Officer & Head of Corporation Devel.(age: 60, pay: $641,330)
    • Ms. Kimberlee Cobleigh Drapkin CPA, CPA Chief Financial Officer & Treasurer(age: 57, pay: $582,390)
  • How many employees does Jounce Therapeutics have?

    As Jul 2024, Jounce Therapeutics employs 141 workers.

  • When Jounce Therapeutics went public?

    Jounce Therapeutics, Inc. is publicly traded company for more then 8 years since IPO on 26 Jan 2017.

  • What is Jounce Therapeutics's official website?

    The official website for Jounce Therapeutics is jouncetx.com.

  • Where are Jounce Therapeutics's headquarters?

    Jounce Therapeutics is headquartered at 780 Memorial Drive, Cambridge, MA.

  • How can i contact Jounce Therapeutics?

    Jounce Therapeutics's mailing address is 780 Memorial Drive, Cambridge, MA and company can be reached via phone at 857 259 3840.

Jounce Therapeutics company profile:

Jounce Therapeutics, Inc.

jouncetx.com
Exchange:

NASDAQ

Full time employees:

141

Industry:

Biotechnology

Sector:

Healthcare

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

780 Memorial Drive
Cambridge, MA 02139

CIK: 0001640455
ISIN: US4811161011
CUSIP: 481116101